Journal Mobile Options
Table of Contents
Vol. 96, No. 3, 2004
Issue release date: March 2004

Bartter’s and Gitelman’s Syndromes: From Gene to Clinic

Naesens M. · Steels P. · Verberckmoes R. · Vanrenterghem Y. · Kuypers D.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Bartter’s and Gitelman’s syndromes are characterized by hypokalemia, normal to low blood pressure and hypochloremic metabolic alkalosis. Recently, investigators have been able to demonstrate mutations of six genes encoding several renal tubular transporters and ion channels that can be held responsible for Bartter’s and Gitelman’s syndromes. Neonatal Bartter’s syndrome is caused by mutations of NKCC2 or ROMK, classic Bartter’s syndrome by mutations of ClC-Kb, Bartter’s syndrome associated with sensorineural deafness is due to mutations of BSND, Gitelman’s syndrome to mutations of NCCT and Bartter’s syndrome associated with autosomal dominant hypocalcemia is linked to mutations of CASR. We review the pathophysiology of these syndromes in relation to their clinical presentation.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Bartter FC, Pronove P, Gill J, MacCardle RC: Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis: A new syndrome. Am J Med 1962;33:811–828.
  2. Gitelman HJ, Graham JB, Welt LG: A new familial disorder characterized by hypokalemia and hypomagnesemia. Trans Assoc Am Physicians 1966;79:221–233.
  3. Madrigal G, Saborio P, Mora F, Rincon G, Guay-Woodford LM: Bartter syndrome in Costa Rica: A description of 20 cases. Pediatr Nephrol 1997;11:296–301.
  4. Scheinman SJ, Guay-Woodford LM, Thakker RV, Warnock DG: Genetic disorders of renal electrolyte transport. N Engl J Med 1999;340:1177–1187.
  5. Rodríguez-Soriano J: Bartter and related syndromes: The puzzle is almost solved. Pediatr Nephrol 1998;12:315–327.
  6. Guay-Woodford LM: Bartter syndrome: Unraveling the pathophysiologic enigma. Am J Med 1998;105:151–161.
  7. Mongeau JG, Garay R, De Mendonca M, Broyer M, Meyer P: Erythrocyte Na+ and K+ transport systems in children with Bartter syndrome: Increase in passive sodium permeability. Kidney Int 1983;23:530–535.
  8. Sechi LA, Melis A, Bartoli E: Abnormalities of erythrocyte in sodium transport systems in Bartter’s syndrome. Am J Nephrol 1992;12:137–143.
  9. Monnens L, Bindels R, Grünfeld JP: Gitelman syndrome comes of age. Nephrol Dial Transplant 1998;13:1617–1619.
  10. Cruz DN, Shaer AJ, Bia MJ, Lifton RP, Simon DB: Gitelman’s syndrome revisited: An evaluation of symptoms and health-related quality of life. Kidney Int 2001;59:710–717.
  11. Calò L, Punzi L, Semplicini A: Hypomagnesemia and chondrocalcinosis in Bartter’s and Gitelman’s syndrome: Review of the pathogenetic mechanisms. Am J Nephrol 2000;20:347–350.
  12. Bettinelli A, Tosetto C, Colussi G, Tommasini G, Edefonti A, Biancheti MG: Electrocardiogram with prolonged QT interval in Gitelman disease. Kidney Int 2002;62:580–584.
  13. Bettinelli A, Metta MG, Perini A, Basilico E, Santeramo C: Long-term follow-up of a patient with Gitelman’s syndrome. Pediatr Nephrol 1993;7:67–68.
  14. Bonfante L, Davis PA, Spinello M, Antonello A, D’Angelo A, Semplicini A, Calo L: Chronic renal failure, end-stage renal disease, and peritoneal dialysis in Gitelman’s syndrome. Am J Kidney Dis 2001;38:165–168.

    External Resources

  15. Bettinelli A, Bianchetti MG, Girardin E, Caringella A, Cecconi M, Appiani AC, Pavanello L, Gastaldi R, Isimbaldi C, Lama G, Marchesoni C, Matteucci C, Patriarca P, Di Natale B, Setzu C, Vitucci P: Use of calcium excretion values to distinguish two forms of primary renal tubular hypokalemic alkalosis: Bartter and Gitelman syndromes. J Pediatr 1992;120:38–43.
  16. Kamel KS, Harvey E, Douek K, Parmar MS, Halperin ML: Studies on the pathogenesis of hypokalemia in Gitelman’s syndrome: Role of bicarbonaturia and hypomagnesemia. Am J Nephrol 1998;18:42–49.
  17. Ring T, Knoers N, Oh MS, Halperin ML: Re-evaluation of the criteria for the clinical diagnosis of Gitelman syndrome. Pediatr Nephrol 2002;17:612–616.
  18. Landau D, Shalev H, Ohaly M, Carmi R: Infantile variant of Bartter syndrome and sensorineural deafness: A new autosomaal recessive disorder. Am J Med Genet 1995;59:454–459.
  19. Jeck N, Reinalter SC, Henne T, Marg W, Mallmann R, Pasel K, Vollmer M, Klaus G, Leonhardt A, Seyberth HW, Konrad M: Hypokalemic salt-losing tubulopathy with chronic renal failure and sensorineural deafness. Pediatrics 2001;108:E5.

    External Resources

  20. Károlyi L, Koch MC, Grzeschik KH, Seyberth HW: The molecular genetic approach to ‘Bartter’s syndrome’. J Mol Med 1998;76:317–325.

    External Resources

  21. Simon DB, Karet FE, Hamdan JM, Di Pietro A, Sanjad SA, Lifton RP: Bartter’s syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat Genet 1996;13:183–188.
  22. Igarashi P, Vanden Heuvel GB, Payne JA, Forbush B: Cloning, embryonic expression and alternative splicing of a murine kidney-specific Na-K-Cl cotransporter. Am J Physiol 1995;269:F405–F418.
  23. Simon DB, Karet FE, Rodriguez-Soriano J, Hamdan JH, DiPietro A, Trachtman H, Sanjad SA, Lifton RP: Genetic heterogeneity of Bartter’s syndrome revealed by mutations in the K+ channel, ROMK. Nat Genet 1996;14:152–156.
  24. Károlyi L, Konrad M, Köckerling A, Ziegler A, Zimmermann DK, Roth B, Wieg C, Grzeschik KH, Koch MC, Seyberth HW, Vargas R, Forestier L, Jean G, Deschaux M, Rizzoni GF, Niaudet P, Antignac C, Feldmann D, Lorridon F, Cougoureux E, Laroze F, Alessandri JL, David L, Saunier P, Deschenes G, Hildebrandt F, Vollmer M, Proesmans W, Brandis M, van den Heuvel LPWJ, Lemmink HH, Nillesen W, Monnens LAH, Knoers NVAM, Guay-Woodford LM, Wright CJ, Madrigal G, Hebert SC: Mutations in the gene encoding the inwardly-rectifying renal potassium channel, ROMK, cause the antenatal variant of Bartter syndrome: Evidence for genetic heterogeneity. Hum Mol Genet 1997;6:17–26.
  25. Jeck N, Derst C, Wischmeyer E, Ott H, Weber S, Rudin C, Seyberth HW, Daut J, Karschin A, Konrad M: Functional heterogeneity of ROMK mutations linked to hyperprostaglandin E syndrome. Kidney Int 2001;59:1803–1811.
  26. Saito-Ohara F, Uchida S, Takeuchi Y, Sasaki S, Hayashi A, Marsumo F, Ikeuchi T: Assignment of the genes encoding the human chloride channels, CLCNKA and CLCNKB, to 1p36 and of CLCN3 to 4q32–q33 by in situ hybridization. Genomics 1996;36:372–374.

    External Resources

  27. Simon DB, Bindra RS, Mansfield TA, Nelson-Williams C, Mendonca E, Stone R, Schurman S, Nayir A, Alpay H, Bakkaloglu A, Rodriguez-Soriano J, Morales JM, Sanjad SA, Taylor CM, Pilz D, Brem A, Trachtman H, Griswold W, Richard GA, John E, Lifton RP: Mutations in the chloride channel gene, CLCNKB, cause Bartter’s syndrome type III. Nat Genet 1997;17:171–178.
  28. Kobayashi K, Uchida S, Mizutani S, Sasaki S, Marumo F: Intrarenal and cellular localization of CLC-K2 protein in the mouse kidney. J Am Soc Nephrol 2001;12:1327–1334.
  29. Vollmer M, Jeck N, Lemmink HH, Vargas R, Feldmann D, Konrad M, Beekmann F, van den Heuvel LPWJ, Deschenes G, Guay-Woodford L, Antignac C, Seyberth HW, Hildebrandt F, Knoers NVAM: Antenatal Bartter syndrome with sensorineural deafness: Refinement of the locus on chromosome 1p31. Nephrol Dial Transplant 2000;15:970–974.
  30. Brennan TM, Landau D, Shalev H, Lamb F, Schutte BC, Walder RY, Mark AL, Carmi R, Sheffield VC: Linkage of infantile Bartter syndrome with sensorineural deafness to chromosome 1p. Am J Hum Genet 1998;62:355–361.
  31. Birkenhäger R, Otto E, Schürmann MJ, Vollmer M, Ruf EM, Maier-Lutz I, Beekman F, Fekete A, Omran H, Feldmann D, Milford DV, Jeck N, Konrad M, Landau D, Knoers NVAM, Antignac C, Sudbrak R, Kispert A, Hildebrandt F: Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. Nat Genet 2001;29:310–314.
  32. Estévez R, Boettger T, Stein V, Birkenhäger R, Otto E, Hildebrandt F, Jentsch TJ: Barttin is a Cl channel β-subunit crucial for renal Cl reabsorption and inner ear K+ secretion. Nature 2001;414:558–561.
  33. Simon DB, Nelson-Williams C, Bia MJ, Ellison D, Karet FE, Molina AM, Vaara I, Iwata F, Cushner HM, Koolen M, Gainza FJ, Gitelman HJ, Lifton RP: Gitelman’s variant of Bartter’s syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet 1996;12:24–30.
  34. Lemmink HH, Knoers NVAM, Károlyi L, van Dijk H, Niaudet P, Antignac C, Guay-Woodford LM, Goodyer PR, Carel JC, Hermes A, Seyberth HW, Monnens LAH, van den Heuvel LPWJ: Novel mutations in the thiazide-sensitive NaCl cotransporter gene in patients with Gitelman syndrome with predominant localization to the C-terminal domain. Kidney Int 1998;54:720–730.
  35. Kurtz I: Molecular pathogenesis of Bartter’s and Gitelman’s syndromes. Kidney Int 1998;54:1396–1410.
  36. Watanabe S, Fukumoto S, Chang H, Takeuchi Y, Hasegawa Y, Okazaki R, Chikatsu N, Fujita T: Association between activating mutations of calcium-sensing receptor and Bartter’s syndrome. Lancet 2002;360:692–694.
  37. Vargas-Poussou R, Huang C, Hulin P, Houillier P, Jeunemaître X, Paillard M, Planneles G, Déchaux M, Miller RT, Antignac C: Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome. J Am Soc Nephrol 2002;13:2259–2266.
  38. Brown EM, MacLeod RJ: Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 2001;81:239–297.
  39. Giebisch G: Renal potassium transport: mechanisms and regulation. Am J Physiol 1998;274:F817–F833.
  40. Kamel KS, Oh MS, Halperin ML: Bartter’s, Gitelman’s and Gordon’s syndromes. Nephron 2002;92(suppl 1):18–27.
  41. Ellison DH: Divalent cation transport by the distal nephron: Insights from Bartter’s and Gitelman’s syndromes. Am J Physiol 2000;279:F616–F625.
  42. Peters M, Jeck N, Reinalter S, Leonhardt A, Tönshoff B, Klaus G, Konrad M, Seyberth HW: Clinical presentation of genetically defined patients with hypokalemic salt-losing tubulopathies. Am J Med 2002;112:183–190.
  43. Boim MA, Ho K, Shuck ME, Bienkowski MJ, Block JH, Slightom JL, Yang Y, Brenner BM, Hebert SC: ROMK inwardly rectifying ATP-sensitive K+ channel II. Cloning and distribution of alternative forms. Am J Physiol 1995;268:F1132–F1140.
  44. Finer G, Shalev H, Birk OS, Galron D, Jeck N, Sinai-Treiman L, Landau D: Transient neonatal hyperkalemia in the antenatal (ROMK-defective) Bartter syndrome. J Pediatr 2003;142:318–323.
  45. Jeck N, Konrad M, Hess M, Seyberth HW: The diuretic- and Bartter-like salt-losing tubulopathies. Nephrol Dial Transplant 2000;15(suppl 6):19–20.
  46. Waldegger S, Jeck N, Barth P, Peters M, Vitzthum H, Wolf K, Kurtz A, Konrad M, Seyberth HW: Barttin increases surface expression and changes current properties of ClC-K channels. Pflügers Arch 2002;444:411–418.
  47. Uchida S: Physiological role of CLC-K1 chloride channel in the kidney. Nephrol Dial Transplant 2000;15(suppl 6):14–15.
  48. Hunter M: Accessory to kidney disease. Nature 2001;414:502–503.
  49. Wall SM, Fischer MP: Contribution of the Na+-K+-2Clcotransporter (NKCC1) to transepithelial transport of H+, NH4+, and Na+ in rat outer medullary collecting duct. J Am Soc Nephrol 2002;13:827–835.
  50. Schuster VL: Function and regulation of collecting duct intercalated cells. Annu Rev Physiol 1993;55:267–288.
  51. Petrovic S, Barone S, Xu J, Conforti L, Ma L, Kujala M, Kere J, Soleimani M: SLC26A7: A basolateral Cl/HCO3 exchanger specific to intercalated cells of outer medullary collecting duct. Am J Physiol 2004;286:F161–F169. E-pub Sept 9, 2003.
  52. Fernández R, Malnic G: H+ ATPase and Cl interaction in regulation of MDCK cell pH. J Membr Biol 1998;163:137–145.
  53. Neyroud N, Tesson F, Denjoy I, Leibovici M, Donger C, Barhanin J, Faure S, Gary F, Coumel P, Petit C, Schwartz K, Guicheney P: A novel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome. Nat Genet 1997;15:186–189.
  54. Marcus DC, Wu T, Wangemann P, Kofuji P: KCNJ10 (Kir4.1) potassium channel knockout abolishes endocochlear potential. Am J Physiol 2002;282:C403–C407.
  55. Flagella M, Clarke LL, Miller ML, Erway LC, Giannella RA, Andringa A, Gawenis LR, Kramer J, Duffy JJ, Doetschman T, Lorenz JN, Yamoah EN, Cardell EL, Shull GE: Mice lacking the basolateral Na-K-2Cl cotransporter have impaired epithelial chloride secretion and are profoundly deaf. J Biol Chem 1999;274:26946–26955.
  56. Delpire E, Lu J, England R, Dull C, Thorne T: Deafness and imbalance associated with inactivation of the secretory Na-K-2Cl cotransporter. Nat Genet 1999;22:192–195.
  57. Karet FE: Inherited distal renal tubular acidosis. J Am Soc Nephrol 2002;13:2178–2184.
  58. Stover EH, Borthwick KJ, Bavalia C, Eady N, Fritz DM, Rungroj N, Giersch AB, Morton CC, Axon PR, Akil I, Al-Sabban EA, Baguley DM, Bianca S, Bakkaloglu A, Bircan Z, Chauveau D, Clermont MJ, Guala A, Hulton SA, Kroes H, Li Volti G, Mir S, Mocan H, Nayir A, Ozen S, Rodriguez-Soriano J, Sanjad SA, Tasic V, Taylor CM, Topaloglu R, Smith AN, Karet FE: Novel ATP6V1B1 and ATP6V0A4 mutations in autosomal recessive distal renal tubular acidosis with new evidence of hearing loss. J Med Genet 2002;39:796–803.
  59. Karet FE, Finberg KE, Nelson RD, Nayir A, Mocan H, Sanjad SA, Rodriguez-Soriano J, Santos F, Cremers CW, Di Pietro A, Hoffbrand BI, Winiarski J, Bakkloglu A, Ozen S, Dusunsel R, Goodyer P, Hulton SA, Wu DK, Skvorak AB, Morton CC, Cunningham MJ, Jha V, Lifton RP: Mutations in the gene encoding B1 subunit of H+-ATPase cause renal tubular acidosis with sensorineural deafness. Nat Genet 1999;21:84–90.
  60. Garel L, Filiatrault D, Robitaille P: Nephrocalcinosis in Bartter’s syndrome. Pediatr Nephrol 1988;2:315–317.
  61. Wrong O: Nephrocalcinosis; in Cameron S (ed): Oxford Textbook of Clinical Nephrology. New York, Oxford University Press, 1998, pp 1381–1383.
  62. Kim YG, Kim B, Kim MK, Chung SJ, Han HJ, Ryu JA, Lee YH, Lee JY, Huh W, Oh HY: Medullary nephrocalcinosis associated with long-term furosemide abuse in adults. Nephrol Dial Transplant 2001;16:2303–2309.
  63. Hoenderop JG, Nilius B, Bindels RJ: Epithelial calcium channels: From identification to function and regulation. Pflügers Arch 2003;446:304–308.
  64. Colussi G, De Ferrari ME, Tedeschi S, Prandoni S, Syrén ML, Civati G: Bartter syndrome type 3: An unusual cause of nephrolithiasis. Nephrol Dial Transplant 2002;17:521–523.
  65. Wagner C, Jensen BL, Krämer BK, Kurtz A: Control of the renal renin system by local factors. Kidney Int 1998;54(suppl 67):78–83.
  66. Schweda F, Wagner C, Krämer BK, Schnermann J, Kurtz A: Preserved macula densa-dependent renin secretion in A1 adenosine receptor knockout mice. Am J Physiol 2003;284:F770–F777.
  67. Bock HA, Hermle M, Brunner FP, Thiel G: Pressure dependent modulation of renin release in isolated perfused glomeruli. Kidney Int 1992;41:275–280.
  68. Kammerl MC, Nüsing RM, Richthammer W, Krämer BK, Kurtz A: Inhibition of COX-2 counteracts the effects of diuretics in rats. Kidney Int 2001;60:1684–1691.
  69. Kammerl MC, Nüsing RM, Seyberth HW, Riegger GA, Kurtz A, Krämer BK: Inhibition of cyclooxygenase-2 attenuates urinary prostanoid excretion without affecting renal renin expression. Pflügers Arch 2001;442:842–847.
  70. Schnermann J: Cyclooxygenase-2 and macula densa control of renin secretion. Nephrol Dial Transplant 2001;16:1735–1738.
  71. Traynor TR, Smart A, Briggs JP, Schnermann J: Inhibition of macula densa-stimulated renin secretion by pharmacological blockade of cyclooxygenase-2. Am J Physiol 1999;277:F706–F710.
  72. Kurtz A, Wagner C: Role of nitric oxide in the control of renin secretion. Am J Physiol 1998;275:F849–F862.
  73. Harris RC: Cyclooxygenase-2 and the kidney: functional and pathophysiological implications. J Hypertens 2002;20(suppl 6):3–9.
  74. Briggs JP, Lorenz JN, Weihprecht H, Schnermann J: Macula densa control of renin secretion. Renal Physiol Biochem 1991;14:164–174.
  75. Schlatter E, Salomonsson M, Persson AE, Greger R: Macula densa cells sense luminal NaCl concentration via furosemide sensitive Na+2ClK+ cotransport. Pflügers Arch 1989;414:286–290.
  76. Schlatter E: Effect of various diuretics on membrane voltage of macula densa cells. Whole-cell patch-clamp experiments. Pflügers Arch 1993;423:74–77.
  77. Persson AE, Salomonssson M, Westerlund P, Greger R, Schlatter E, Gonzalez E: Macula densa cell function. Kidney Int 1991;39(suppl 32):39–44.
  78. White PC: Disorders of aldosterone biosynthesis and action. N Engl J Med 1994;331:250–258.
  79. Yuan BH, Robinette JB, Conger JD: Effect of angiotensin II and norepinephrine on isolated rat afferent and efferent arterioles. Am J Physiol 1990;258:F741–F750.
  80. Ichikawi I, Harris RC: Angiotensin actions in the kidney: Renewed insights into the old hormone. Kidney Int 1991;40:583–596.
  81. Chiou CY, Kifor I, Moore TJ, Williams GH: The effect of losartan on potassium-stimulated aldosterone secretion in vitro. Endocrinology 1994;134:2371–2375.
  82. Hilbers U, Peters J, Bornstein SR, Correa FMA, Jöhren O, Saavedra JM, Ehrhart-Bornstein M: Local renin-angiotensin system is involved in K+-induced aldosterone secretion from human adrenocortical NCI-H295 cells. Hypertension 1999;33:1025–1030.
  83. Konrad M, Leonhardt A, Hensen P, Seyberth HW, Köckerling A: Prenatal and postnatal management of hyperprostaglandin E syndrome after genetic diagnosis from amniocytes. Pediatrics 1999;103:678–683.
  84. Warnock DG: Nitric oxide and Bartter and Gitelman syndromes. Kidney Int 2001;60:1197–1198.
  85. Calò L, Ceolotto G, Milani M, Pagnin E, van den Heuvel LP, Sartori M, Davis PA, Costa R, Semplicini A: Abnormalities of Gq-mediated cell signaling in Bartter and Gitelman syndromes. Kidney Int 2001;60:882–889.
  86. Stoff JS, Stemerman M, Steer M, Salzman E, Brown RS: A defect in platelet aggregation in Bartter’s syndrome. Am J Med 1980;68:171–180.
  87. Clive DM, Stoff JS, Cardi M, MacIntyre DE, Brown RS, Salzman EW: Evidence that circulating 6-keto-prostaglandin E1 causes the platelet defect of Bartter’s syndrome. Prostaglandins Leukot Essent Fatty Acids 1990;41:251–258.
  88. Bettinelli A, Bianchetti MG, Borella P, Volpini E, Metta MG, Basilico E, Selicorni A, Bargellini A, Grassi MR: Genetic heterogeneity in tubular hypomagnesemia-hypokalemia with hypocalcuria (Gitelman’s syndrome). Kidney Int 1995;47:547–551.
  89. Whang R, Whang DD, Ryan MP: Refractory potassium depletion. A consequence of magnesium deficiency. Arch Intern Med 1992;152:40–45.
  90. Reilly RF, Ellison DH: Mammalian distal tubule: Physiology, pathophysiology and molecular anatomy. Phys Rev 2000;80:277–309.
  91. Hoenderop JG, van der Kemp AW, Hartog A, van Os CH, Willems PH, Bindels RJ: The epithelial calcium channel, ECaC, is activated by hyperpolarization and regulated by cytosolic calcium. Biochem Biophys Res Commun 1999;261:488–492.

    External Resources

  92. Nijenhuis T, Hoenderop JGJ, Loffing J, van der Kemp AWCM, van Os CH, Bindels RJM: Thiazide-induced hypocalciuria is accompanied by a decreased expression of Ca2+ transport proteins in kidney. Kidney Int 2003;64:555–564.
  93. Knoers NV, de Jong JC, Meij IW, Van Den Heuvel LP, Bindels RJ: Genetic renal disorders with hypomagnesemia and hypocalciuria. J Nephrol 2003;16:293–296.
  94. Dai LJ, Ritchie G, Kerstan D, Kang HS, Cole DE, Quamme GA: Magnesium transport in the renal distal convoluted tubule. Physiol Rev 2001;81:51–84.
  95. Kiuchi-Saishin Y, Gotoh S, Furuse M, Takasuga A, Tano Y, Tsukita S: Differential expression patterns of claudins, tight junction membrane proteins, in mouse nephron segments. J Am Soc Nephrol 2002;13:875–886.
  96. Simon DB, Lu Y, Choate KA, Velazquez H, Al-Sabban E, Praga M, Casari G, Bettinelli A, Colussi G, Rodriguez-Soriano J, McCredie D, Milford D, Sanjad S, Lifton RP: Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption. Science 1999;285:103–106.
  97. Weber S, Schlingmann KP, Peters M, Nejsum LM, Nielsen S, Engel H, Grzeschik KH, Seyberth HW, Gröne HJ, Nüsing R, Konrad M: Primary gene structure and expression studies of rodent paracellin-1. J Am Soc Nephrol 2001;12:2664–2672.
  98. Bettinelli A, Consonni D, Bianchetti MG, Colussi G, Casari G: Aldosterone influences serum magnesium in Gitelman syndrome. Nephron 2000;86:236.
  99. Dai LJ, Friedman PA, Quamme GA: Cellular mechanisms of chlorothiazide and cellular potassium depletion on Mg2+ uptake in mouse distal convoluted tubule cells. Kidney Int 1997;51:1008–1017.
  100. Schultheis PJ, Lorenz JN, Meneton P, Nieman ML, Riddle TM, Flagella M, Duffy JJ, Doetschman T, Miller ML, Shull GE: Phenotype resembling Gitelman’s syndrome in mice lacking the apical Na+-Cl cotransporter of the distal convoluted tubule. J Biol Chem 1998;273:29150–29155.
  101. Cole DE, Quamme GA: Inherited disorders of renal magnesium handling. J Am Soc Nephrol 2000;11:1937–1947.
  102. Loffing J, Loffing-Cueni D, Hegyi I, Kaplan MR, Hebert SC, Le Hir M, Kaissling B: Thiazide treatment of rats provokes apoptosis in distal tubule cells. Kidney Int 1996;50:1180–1190.
  103. Kaissling B, Loffing J: Cell growth and cell death in renal distal tubules, associated with diuretic treatment. Nephrol Dial Transplant 1998;13:1341–1343.
  104. Gascón A, Cobeta-Garcia JC, Iglesias E: Hypomagnesemia and chondrocalcinosis in Gitelman syndrome. Am J Med 1999;107:301–302.
  105. Lüthy C, Bettinelli A, Iselin S, Metta MG, Basilico E, Oetliker OH, Bianchetti MG: Normal prostaglandinuria E2 in Gitelman’s syndrome, the hypocalciuric variant of Bartter’s syndrome. Am J Kidney Dis 1995;25:824–828.
  106. Patak RV, Fadem SZ, Rosenblatt SG, Lifschitz MD, Stein JH: Diuretic-induced changes in renal blood flow and prostaglandin E excretion in the dog. Am J Physiol 1979;236:F494–F500.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50